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ABSTRACT 
Allogeneic stem cell transplantation (SCT) is a curative treatment for malignant and non-malignant 
diseases. However, transplantation related morbidity and mortality are major drawbacks affecting the 
survival and life quality of the patients. The major complications of SCT are infections, hemorrhagic 
cystitis, liver toxicity, interstitial pneumonia and GVHD. Busulphan (Bu), treosulfan (Tr) and 
cyclophosphamide (Cy) are alkylating agents. They are currently used in high doses as preparative 
regimen before SCT. Pharmacokinetics and pharmacodynamics of these drugs have been intensively 
studied with the aim of defining a therapeutic window to achieve a satisfactory myeloablation and 
immunosuppression with less treatment related toxicity. 
Study I:  We administered N-acetyl-L-cysteine (NAC) during conditioning to patients at risk of 
Sinusoidal obstructive Syndrome (SOS) due to pretransplant liver disorders or elevated liver enzymes. No 
side effects related to the NAC administration were observed and Bu-kinetics was not affected. All 
patients became pancytopenic and engrafted with100% donor cells. None of the patients developed SOS 
or liver failure. Increased liver enzymes during conditioning decreased or normalized in all patients. We 
suggested that NAC therapy is safe and does not impair the myeloablative effect of Bu during 
conditioning prior to SCT and hence NAC may be an effective prophylactic treatment against SOS and 
hepatic toxicity during conditioning. 
Study II In a preclinical study, myeloablative as well as immunosuppressive properties of Tr were 
compared with those of Bu and Cy in a mouse model. The animals were treated with Tr, Cy, or Bu at 
sublethal doses that maintained survival without bone marrow support. The myeloablative effect was 
evaluated using colony-forming unit granulocyte macrophages (CFU-GM), while the immunological 
effect was performed using spleen cells. We found that Tr and Bu induced a high and persistent 
myeloablation compared to Cy. Moreover, Tr was more effective in depletion splenic B and T cells 
compared to Bu and Cy. T-cells isolated from the spleens of Tr- or Bu-treated mice were not responsive to 
allogeneic cells compared with those observed in Cy treated mice. Our findings suggested that Tr 
possesses both myeloablative and immunosuppressive properties and may be used as a single agent for 
conditioning prior to SCT. 
Study III. Therapeutic drug monitoring (TDM) of Bu-iv was performed in 34 pediatric SCT patients. Bu-
iv was administered twice daily according to recommended weight-based doses. Bu levels were measured 
and pharmacokinetic analysis was performed. The targeted Bu exposure was aimed to range between 
areas under the curve (AUC) of 9000–12000 ng/mLxh. In 23/34 patients (68%) Bu dose had to be 
adjusted at least once. In 16/23 patients the dose had to be increased in a range of 7-33%, while in 7/23 
patients (30%) the dose had to be decreased by 7-20%. The need of dose adjustment was not related to 
weight, age or underlying disease. SOS was observed in 21% of the patients in spite of total AUC’s within 
the target AUC. We concluded that TDM of iv Bu is essential to increase the efficacy and safety of Bu-
based conditioning protocols in pediatric HSCT recipients. 
Study IV. Limited sampling models for use in TDM of Bu in patients treated for hematologic 
malignancies. 23 patients were sampled according to standard protocol (8 samples). AUC calculated from 
three limited sampling models were compared with WinNonLin compartment modeling. Combining a 
curve fitting model and a compartment model, using the average AUC estimate, gave a concordance 
correlation coefficient of 0.85 with the described standard sampling protocol. Using Bland-Altman plots it 
was evident that most patients would have been treated the same regarding dose adjustment using the 
combined method as well as standard rich sampling. The results support the use of limited sampling in 
clinical therapeutic drug monitoring, provided adequate algorithms are used for evaluation. Both models 
included in the combined method utilized four concentrations points. The model is reliable, solid and user 
friendly providing the clinician with a graph and a numeric AUC estimate. 
These four studies taken together may provide a step forward in treatment optimization and dose 
individualization to the benefit of SCT patients. 
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1. INTRODUCTION 
Drugs of varying kinds have been used since ancient times to fight disease. From old 
herbal remedies to modern bioengineered molecules, the means have changed but the 
goal remains the same: expedient cure and no adverse effects. Even if we may have 
come a long way since Hippocrates and Galen, a panacea for all human illness still 
seems far away.  
The discoveries of modern biology and medicine have given us a dramatically widened 
perspective, but it has also unveiled the complexity of disease and in some cases 
produced more questions than answers. As doctors we can no longer hope for 
restitution of homeostasis in bodily fluids to be a cure for cancer or infection; instead, 
we have to combat microbes and malignant cells capable of adapting to and 
counteracting our moves in apparently deliberate ways.  
Cancer is a disease as old as mankind; the Edwin Smith papyrus and the Ramayana 
describe malignant diseases and their treatments[1-3]. Most frequently therapy 
consisted of topical preparations, although removal of neoplasms had been practiced in 
old Egypt[3]. Mastectomy was described during the Roman period by Celsus and 
Leonides[4]. In the first century A.D., Dioscorides compiled a list of medicinal herbs 
and botanicals[5], including topical applications for treatment of tumors and 
carcinomas. By the beginning of the eleventh century, an Arabic physician, Avicenna 
“Ibn Sina”, used the arsenic therapy systemically to treat leukemia; however, due to its 
high toxicity, it received little attention[6]. Preparations containing Arsenic known as 
Unguentum Aegypticum were used topically until late sixteenth century[6]. Potassium 
arsenite was reintroduced by Lissauer in 1865 as the first instance of effective 
chemotherapy to treat chronic myelogenous leukemia[7]. The use of Arsenic 
compounds (Fowler's solution) to treat leukemia continued until the 1930s[8]. 
Surprisingly, the use of arsenical therapy (arsenic trioxide) has become a part of 
modern therapy during the last decade and is now established as an effective treatment 
for acute promyelocytic leukemia (AML-M3) [9-10].  
The cure for cancer has been sought for since the dawn of modern medicine, but for 
most patients with disseminated cancer it still remains elusive. There are, however, 
some malignancies for which the prognosis of disseminated disease has indeed 
improved considerably; treatment options for leukemia 75 years ago were generally 
limited to radiation therapy and arsenic with a prognosis of less than 10-15% long term 
survival[11].  Today we have an arsenal of treatments available that can cure or long-
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term stabilize leukemia, ranging from tyrosine kinase inhibitors to blood stem cell 
transplantation. The prospect for these patients has changed dramatically. It is 
somewhat notable that in most cases this progress has come from new means of dealing 
with toxicity and adverse effects rather than from utilizing principally new drug targets 
or mechanisms. The now well established graft-versus-leukemia effect can be 
considered a novel treatment principle, but radiation and alkylating agents that 
constitute the basis for most conditioning regimens in allogeneic stem cell 
transplantation were discovered as early as a century ago. 
At least for now, optimizing therapy and the use of known drugs in new ways have 
been the basis of most of the progress made in improving the prognosis for patients 
suffering from malignant disease. Even if the advent of targeted drug development and 
recombinant gene technology may change that in the future, it is my belief that 
improving the use of known therapeutic principles and drugs will remain an important 
task and that pharmacokinetic and pharmacodynamic studies will continue to play a 
key role in such efforts. 
The work for my thesis focuses on drug toxicity and optimization of treatment, 
specifically the improvement of myeloablative treatment as conditioning before 
allogeneic stem cell transplantation. 
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1.1 THE DEVELOPMENT OF CANCER TREATMENT 
 Alkylating agents were the first non-hormonal agents to show significant antitumor 
activity in humans [12-13]. The clinical trials of nitrogen mustards 
in patients with hematologic malignancies evolved from clinical 
observations of the victims of sulfur mustard gas used in World 
War I. This compound was found to produce more or less extreme 
leucopenia, which followed an initial leukocytosis. It is interesting 
to note that survival of mustard gas exposition was found to 
correlate inversely to post exposure leukocyte counts, just as is the 
case with accidental radiation exposure [14-15]. The time sequence 
of marrow depression revealed a maximal effect at two weeks after exposure when 
mortality was highest. Deaths were attributed to pneumonia associated with leucopenia 
as reported by Krumbhaar and Krumbhaar in 1919. The related, but less reactive, 
nitrogen mustards were found to be less toxic and to cause regression of lymphoid 
tumors in mice. The first clinical studies produced dramatic effects in lymphoma 
patients, and the antitumor effects in lymphoid malignancies were confirmed by an 
organized multi-institution study [12-13]. Investigation of the mechanism behind the 
observed biological effects revealed chromosome breakage due to cross-linking 
alkylation in cells treated with nitrogen mustards[16]. Alkylating agents still occupy a 
central position in cancer chemotherapy, both in conventional regimens and in high-
dose protocols with allogeneic or autologous stem cell support. The first compound of 
the nitrogen mustard group examined for clinical use was mechlorethamine. After its 
introduction, several analogues in which the methyl group was replaced by other 
chemical groups were synthesized and tested for antitumor activity. Among them the 
well-known substances melphalan, chlorambucil, cyclophosphamide and ifosfamide 
were found to have a higher therapeutic index and a broader range of clinical activity, 
and they have now replaced mechlorethamine in clinical use.  
In the 1950s Timmis and coworkers introduced a new class of compounds. They found 
that compounds with one to eight methylene units placed between two sulfonate groups 
have alkylating and antitumor activity and that maximal activity is shown by the 
compound with four methylene units, busulphan [17-18]. 
HG&EB Krumbhaar, 
1918 
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Generally today, the antineoplastic agents are used for the purpose of killing cancer 
cells. Therefore the terms cancer chemotherapeutic drugs and cytotoxic compounds are 
interchangeable. Cancer drugs used today can generally be classified into classes such 
as Alkylating agents, Antimetabolites, Antitumor antibiotics, Topoisomerase inhibitors, 
Alkaloids and Podophylotoxins.  
Among these drugs, the alkylating agents are the cornerstones of cancer treatment.  
Several other treatments like gene therapy, hormone treatment and cell therapy have 
been introduced in clinical use. Stem cell transplantation has introduced a curative 
treatment both for malignant and non- malignant diseases, as well as for different 
metabolic and genetic disorders. 
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1.2 HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) 
HSCT is a procedure where hematopoietic stem cells are given to a recipient with the 
intention of replacing the recipient’s own hematopoietic system in whole or in part. The 
stem cells can be derived from bone marrow, peripheral blood or cord blood. If the 
donor is the same person as the recipient it is called an autologous HSCT. If the donor 
is genetically identical to the recipient, as is the case for identical twins, we have a 
syngeneic HSCT. The syngeneic HSCT biology is immunologically equal to that of an 
autologous HSCT. HSCT with any other type of human donor, related or unrelated, is 
referred to as an allogeneic HSCT. An autologous transplantation is done in order to 
save the patient from the toxic effects of a high-dose treatment that would otherwise 
cause permanent or long-lasting aplasia of hematopoietic stem cells, a condition which 
is often lethal. The positive aspect of an autologous HSCT is that it does not cause graft 
versus host disease, and there is no risk for rejection. On the other hand, it does not 
offer any chance for immunologic graft versus tumor effect. Autologous HSCT is an 
important treatment modality, but it is not part of my research project. When I use the 
term HSCT without a qualifier in the rest of this text, I am referring to allogeneic 
HSCT. 
Encouraged by the progress made in the first decades of the 20th century in treating 
pernicious anemia and iron deficiency anemia, medical researchers speculated that all 
kinds of blood disease could be cured by adding a “deficiency substance”. Since this 
substance would have to be present in normally functioning bone marrow, it was 
presumed that providing healthy bone marrow extracts to the patient could cure aplastic 
anemia, granulocythopenia et cetera. Interestingly, oral administration provided results 
as beneficial as did sternal intraosseus administration[19-20]. The patients in these 
reports obviously had granulocythopenia caused by infection or other transient factors, 
and we now know that there is no “deficiency substance” that can cure aplastic anemia 
or leukemia patients. These unmatched bone marrow transplantation recipients would 
probably have died from graft versus host disease in the unlikely event of a successful 
bone marrow engraftment. Luckily for them, only patients with severe T-cell defect 
would run any risk for that from the procedures described, and it would take many 
years before graft versus host disease was reported in man. 
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During experiments with immunologically immature or deficient animals in the 1950s, 
it was found that an infusion of allogeneic leukocytes could react to the host and 
produce a lethal syndrome of wasting, hepatitis, dermatitis, aplastic anemia and 
diarrhea[21]. The probability of this reaction is correlated to the amount of allogeneic 
leukocytes given and the degree of immunodeficiency in the recipient. Blood 
transfusions had become an increasingly feasible clinical procedure during the first half 
of the 20th century, and with the dawning awareness that allogeneic leukocytes can 
cause this syndrome it was just a matter of time before an accidental case would be 
found in man. In 1965 the first proved cases were reported in two immunodeficient 
infants, who had received repeated blood transfusions due to smallpox vaccination 
complications. In both cases the syndrome was lethal[22]. By then, experiments in 
which patients were given intravenous bone marrow infusions had already been 
reported. In 1957 no adverse effects were seen from this procedure in a series of six 
patients. Even though recipients had received immunosuppressive treatments like 
radiation and busulphan, transiently circulating donor blood cells were found only in 
two patients, indicating the failure of permanent marrow engraftment. The author and 
later Nobel Prize laureate noted that no adverse effects had been seen. He further 
acknowledged that a graft versus host reaction may had been seen in animal 
experiments, but that the risk for occurrence in patients given sufficient 
immunosuppressive treatment for permanent engraftment was still “a matter of 
speculation”[23]. In 1963 the first successful bone marrow transplantation was reported 
in a patient with acute lymphoblastic leukemia who received a bone marrow mix from 
relatives. After what most reasonably was a moderate graft versus host disease, the 
cells of the donor with the best match in HLA-A took over and the rash and diarrhea 
resolved. Unfortunately, the patient later died from infectious complications[24]. From 
this, and from animal experiments, it was understood that bone marrow from a donor 
with a major histocompatibility locus identical to that of the recipient was more likely 
to engraft and less likely to produce a graft versus host reaction. Using HLA-matching, 
an infant with Wiskott Aldrich Syndrome was successfully transplanted with bone 
marrow from an HLA-A identical sibling after receiving immunosuppressive treatment 
with cyclophosphamide[25]. Successful treatment of aplastic anemia and leukemia with 
hematopoietic stem cell transplantation followed, but so did casualties from 
cytomegalovirus infections and other lethal adverse effects of the procedure[26-28]. 
Within a decade of the first successful hematopoietic stem cell transplantations, a team 
at Karolinska-Huddinge performed Sweden’s first HSCT in 1975[29]. Today, HSCT is 
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a well-established curative procedure for several malignant and nonmalignant disorders 
in children as well as in adults[30]. The main problem with HSCT remains toxicity, 
limiting the use of this treatment to young patients free from serious co-morbidities. 
Even in this patient group, the procedure is dangerous and stressful. Cytomegalovirus 
killed the first successful transplantation patient reported in 1968 and was a serious 
threat during the early days of HSCT. Today, screened/filtered blood products, antiviral 
drugs and surveillance protocols have contributed to a low frequency of CMV related 
mortality[31]. However, even with the protocols refined through experience from the 
more than forty years that have passed since the first HSCT, patients still suffer from 
mucosal damage in the mouth and gastrointestinal tract. The damage of anatomical 
barriers renders the patient susceptible to various infectious agents, and during the 
weeks before the transplanted stem cells are able to produce an adequate amount of 
neutrophils, the patient is virtually defenseless against fungal and bacterial infections. 
Immunosuppressive drugs and slowly regenerating parts of the immune system cause a 
lasting increase in the risk of serious infections. In addition, graft versus host disease 
and malignant diagnose relapse adds to the mortality and morbidity[32]. 
The original combination of total body irradiation (TBI) and cyclophosphamide 
developed in Seattle provides effective immunosuppression and anti-tumor activity, but 
replacing TBI with busulphan is an effective alternative[33-36]. With this regimen one 
can avoid some problems with TBI, particularly growth retardation, cataracts and 
encephalopathy in children [37-38].  Moreover, it makes it possible to perform HSCT 
in centers without TBI facilities. Busulphan and TBI have similar myeloablative 
properties, but a higher engraftment level and a lower number of surviving CFUs in 
TBI treated mice compared to those treated with busulphan have been reported[39]. 
This may indicate a difference in their toxicity and mechanism of action. Despite being 
an effective myeloablative agent, busulphan does not possess sufficient 
immunosuppressive effects [40]. It is therefore of particular importance to add 
immunosuppressive drugs such as cyclophosphamide to busulphan based protocols in 
order to achieve an ideal pre transplant conditioning regimen.  
The relative merits of the two regimens are still debated, as studies comparing them 
report conflicting results concerning outcome and toxicities[41-43]. The important 
subgroup of unrelated donor transplantations has only recently been evaluated 
according to choice of TBI or busulphan; the results showed similar clinical outcomes 
for transplant recipients with myeloid malignancies indicating that other prognostic 
variables might have a larger influence on survival than the type of ablative preparative 
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regimen[44].  It must be remembered however, that there is presently no generally 
accepted standard strategy to handle the interpatient differencies in busulphan 
metabolism and bioavailabiliy. This becomes apparent in the wide variations in 
busulphan exposure seen when oral busulphan is used as replacement for TBI. Since 
several studies have demonstrated that adequate busulphan exposure levels are vital to 
minimize the risks for complications after HSCT[45-49], it is reasonable to hypothesize 
that this may at least in part explain the contradictory results. 
Reduced Intensity Conditioning Transplantation (RICT) is a method for HSCT based 
on the philosophy of using a minimum of conditioning treatment, primarily 
immunosuppression, with the intent to utilize the immunologic graft versus leukemia 
alone as treatment against the malignant disease[50]. RICT has been shown to have less 
non relapse mortality and morbidity than myeloablative HSCT[51]. RICT is an 
important possibility for patients with co-morbidities excluding them from 
conventional HSCT, but the relapse risk especially in acute leukemia (the most 
common indication for HSCT) is unacceptably high for younger, fitter patients[52]. A 
substantial improvement is needed if RICT is to replace myeloablative treatment as the 
most important preparative strategy before HSCT. The success of HSCT is still limited 
due to several complications, including treatment related toxicity such as Sinusoidal 
obstructive Syndrome (SOS) formerly known as veno occlusive disease or VOD, 
Hemorrhagic cystitis (HC) and interstitial pneumonia (IP). Moreover, graft versus host 
disease and relapse are the most common immunological problems following HSCT.    
 
1.2.1 Sinusoidal obstructive Syndrome (SOS) 
Sinusoidal obstructive Syndrome (SOS) or ‘Veno occlusive disease’ is a serious liver 
complication caused by chemotherapy and/or radiation before HSCT.  The reported 
incidence ranges from 3 to 50% and the mortality rate from 0 to 90 % (median 30 
%)[53-56]. The symptoms usually appear 1-4 weeks after conditioning and are 
jaundice, enlarged liver, pain and tenderness in the area of the liver, rapid weight gain, 
swelling and accumulation of fluid. SOS is diagnosed on the basis of clinical signs - 
that is, the presence of hyperbilirubinemia (total serum bilirubin > 34umol/l) and the 
development of two of the following signs during the first 21 days post-transplant: 
weight gain >5% from preconditioning baseline weight, ascites and/or hepatomegaly. 
[57]  
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1.2.2 Graft versus host disease (GVHD) 
Acute GVHD (aGVHD) remains the major complication of allogeneic SCT. 
Historically it was called the secondary disease, the disease that involved skin, gut and 
liver in allogeneically transplanted mice. It was renamed acute graft versus host disease 
in 1960. The incidence of GVHD ranges between 6-80% following allogeneic SCT, 
and it can be fatal in up to 50 % of cases.[58-60]. Elevated inflammatory Th1 cytokines 
appear to be responsible for the development of acute graft versus host disease 
(GVHD) following bone marrow transplantation (BMT) in a cascade that has been 
termed the ‘cytokine storm’. [61] The development of GVHD has been suggested to 
occur in at least three phases: Phase 1 starts when the inflammatory cytokines (IL-1, 
IL-6, IL-8 and TNF-α) are released. Phase 2 starts with the activation of donor T-cells, 
reacting to up regulated host tissue antigens including human leukocyte antigen (HLA) 
and adhesion molecule expression. Phase 3 involves additional host tissue damage, 
activated T and NK cells, and the release of Th1 cytokines (IL-2,interferon-gamma and 
TNF-α )[61]. It has been shown that increased levels of TNF-α preceded BMT 
complications such as severe acute GVHD, interstitial pneumonitis, endothelial linkage 
syndrome and VOD.[62]. Usually prophylaxis treatment is used during and after SCT. 
Cyclosporine, prednisone and methotrexate are the most commonly used drugs.  
Chronic GVHD (cGVHD) develops three or more months after SCT. The symptoms 
are a dry itchy rash, change in skin color and tautness or tightening of the skin. Liver 
abnormalities, dry or burning eyes, dry mouth, mouth sores, infections and stomach 
irritation are also common symptoms.  
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1.3 CYCLOPHOSPHAMIDE 
As described earlier, cyclophosphamide (Fig 1) belongs to the nitrogen mustard group 
and is one of the most successful mechlorethamine analogues developed for clinical use 
against malignant disease. More than half a century after the introduction of 
cyclophosphamide it is still widely used both orally and intravenously, not only as an 
antineoplastic agent but also for immunosuppression. The pronounced 
immunosuppressive properties of cyclophosphamide have made it an important part of 
the therapeutic arsenal against autoimmune disease and a component of many pre 
transplant conditioning regimens[63].  
Cyclophosphamide is a pro-drug activated by liver P450 enzymes including 2B6, 3A4, 
2C19 and 2C9[64]. Metabolism of cyclophosphamide through the hepatic P450 
enzymatic pathway produces active as well as toxic components, e.g. 4-
hydroxycyclophosphamide(4-OH-Cy), chloroacetaldehyde and acrolein[64]. 4-OHCy 
forms the alkylating agent phosphoramide mustard which alkylates DNA. As 
substantial levels of glutathione are necessary to detoxify these metabolites it may be 
hypothesized that the administration of busulphan before cyclophosphamide may 
increase treatment related toxicity due to the decreased glutathione levels in the liver 
and tissues (after four days of busulphan), given that cyclophosphamide metabolites are 
the main components causing short term toxicity [65-66].  
 
 
 
Figure 1: Cyclophosphamide (N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-
amine 2-oxide) 
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1.4 TREOSULFAN 
Busulphan (Fig 2)  in combination with high-dose cyclophosphamide is one of the most 
common regimens of conditioning treatment prior to allogeneic HSCT. As described 
above, the combination has been in use for many years with only minor changes, 
despite the problems involved in high dose busulphan treatment. It is clear that the 
complicated and erratic pharmacokinetics of busulphan and the risks for, in particular, 
hepatotoxicity warrant the search for replacement drug candidates in the plethora of 
cytostatic agents available. 
Treosulfan (Fig 2), synthesized first by Peter W Feit in 1961[67], is an alkylating agent 
structurally related to busulphan; it has traditionally been used primarily in treatment of 
late-stage ovarian carcinoma. It has many properties that make it interesting as a 
replacement for busulphan. In contrast to busulphan, treosulfan is water-soluble and 
can easily be administered by intravenous infusion.  
Treosulfan in doses exceeding 10 g/m2 carries a high risk for permanent myeloablation, 
but no other frequently occurring toxicity is reported for doses up to 47 g/m2. Beyond 
this dose, toxicities such as diarrhea, mucositis, stomatitis, skin toxicity, and metabolic 
acidosis have been observed. Very few cases of severe liver toxicity or VOD have been 
reported[68-70]. 
 
Figure 2: Busulphan and Treosulfan 
     
 
 
 
In spite of the obvious structural similarities between busulphan and treosulfan, the 
introduction of two hydroxyl moieties fundamentally changes the mechanism of action. 
Treosulfan is in principle a pro-drug that transforms to the active epoxide (2S, 3S)-1, 2; 
3, 4-diepoxybutane (S, S-DEB) and Methanesulfonic acid non-enzymatically. The 
transformation depends mainly on pH and temperature; it is practically halted below 
pH 6.0. S, S-DEB is a bifunctional alkylating agent that has the ability to cross-link 
DNA[71]. The majority of cross-links are supposed to be of the 1, 3-interstrand type, 
causing cytotoxic effects. However, structural changes in DNA that fail to induce cell 
death are responsible for the well documented mutagenic effects of DEB [72-73]. 
Treosulfan Busulphan 
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Treosulfan bioavailability is close to 100% with low interpatient variability, and the 
pharmacokinetics can best be described by a two-compartment model with first-order 
kinetics of distribution, elimination and absorption. There is a linear relationship 
between Cmax and AUC for doses from 20 up to 56g/m². To add to the favorable 
pharmacokinetic profile, available pediatric data indicate no important difference in 
pharmacokinetics between children and adults. About 30% of the total dose 
administered is excreted unchanged into the urine in a patient with normal renal 
function[74]. 
In conclusion, treosulfan possesses several attractive characteristics as a candidate for 
replacing busulphan in conditioning protocols before HSCT.   
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1.5 BUSULPHAN 
 
 
CH3SO2O(CH2)4OSO2CH3 
 
Figure 3: Busulphan (Myleran®) 
 
    
Busulphan (Bu) 1,4-bis(methanesulfonoxy) butane is an alkylating agent. Busulphan 
(Fi 3) was first used in 1952 in low doses for the treatment of chronic myeloic leukemia 
(CML)[75] as well as for the treatment of polycythemia vera (PCV). Busulphan 
belongs to the alkyl alkane sulfonate group of alkylating agents. 
Busulphan alkylates through an SN2 mechanism (Fig. 4), the rate of which is dependent 
on the concentration of both the alkylating agent and the target nucleophile. The 
compound reacts more extensively with thiol groups of amino acids and proteins than 
do the nitrogen mustards, and these findings have prompted the suggestion that the 
alkyl alkane sulfonates, unlike the nitrogen mustards, may exert their cytotoxic 
activities mostly through such reactions rather than through interactions with DNA[76-
77]. In contrast to the nitrogen mustards, busulphan displays a more marked effect on 
myeloid cells than on lymphoid cells, and it was noted early that simultaneous 
administration of busulphan and a nitrogen mustard can imitate the hematological 
effects of radiation[78]. Busulphan is cytotoxic to hematopoietic stem cells. The effect 
is seen clinically in the prolonged aplasia that may be seen after busulphan 
administration and can be shown experimentally in stem cell cloning systems [79-80]. 
Posing problems when busulphan is used as low dose treatment for chronic 
myelogenous leukemia, the characteristics are exploited in high dose conditioning 
protocols for ablative hematopoietic stem cell transplantation [33, 35]. Alkylators are in 
general mutagenic, but there is a considerable difference between the compounds in 
their tendency to induce mutations relative to their cytotoxic effects. Busulphan 
compares unfavorably to most other alkylators in this respect, which means it is not 
suitable for long term therapy due to the risk for secondary malignancies [81-82]. Over 
time other less mutagenic treatment options have become available. Busulphan has 
been replaced by tyrosine kinase inhibitors, interferon and hydroxyurea in non-
myeloablative treatment of chronic myelogenous leukemia and other 
myeloproliferative diseases, and high dose conditioning protocols is now the single 
most important clinical application of busulphan [83-84].  
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Figure 4: Busulphan alkylating mechanism 
 
 
1.5.1 Pharmacokinetics of busulphan 
The unpredictability of busulphan pharmacokinetics is notorious, and when used in 
doses close to maximum tolerated (as in HSCT) over- or under-dosing may have severe 
consequences. Busulphan is a hydrophobic drug; potentially toxic additives and costly 
liposomal packaging are needed to achieve a formulation suitable for intravenous 
administration. Accordingly busulphan is in most cases administered orally, adding 
bioavailability to the factors that affect drug exposure. Bioavailability is known to vary 
extensively, in pediatric patients as much as 2- to 5-fold[85]. Studies have found that 
approximately one third of the total amount of busulphan administered is irreversibly 
bound to plasma proteins and half is irreversibly bound to red blood cells[86]. 
The metabolism and elimination is quite complex (Fig 5), but the parent drug alone 
possesses alkylating activity and the metabolites are believed to be pharmacologically 
inactive. 
Busulphan is deactivated by two mechanisms: 
 
• Busulphan may spontaneously form tetrahydrofuran. This occurs at a low rate 
and is in vivo quantitatively of minor importance.   
• Busulphan is enzymatically conjugated to glutathione. This is the major 
deactivating mechanism, its rate limited by hepatic enzyme function and 
glutathione availability. 
When glutathione is conjugated to busulphan the sulfonium ion of glutathione is 
formed and some of the conjugate is excreted in the bile. The conjugate undergoes 
enzymatic cleavage in the intestine by forming tetrahydrothiophene which may be 
reabsorbed and oxidized in the liver to tetrahydrothiopheneoxide, sulfolane and 
eventually 3-hydroxy-sulfolane. Tetrahydrothiopheneoxide and 3-hydroxy-sulfolane 
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are polar and readily excreted in the urine. Some of the conjugate is metabolized in the 
mercapturic acid pathway to form the sulfonium ion of N-Acetyl-L-Cysteine and then 
excreted in the urine [87-88].  
 
1.5.2 Busulphan metabolism 
As may be inferred from the above description, the metabolism and elimination of 
busulphan (Fig 5) is highly dependent on glutathione. The intracellular concentration 
may be affected by nutritional status, hepatic function et cetera[89]. This may be the 
reason that intra-patient variation in busulphan exposure is even more pronounced than 
the variation in bioavailability, meaning that the latter can only partly be responsible for 
the former[90].   
 
 
Figure 5: Busulphan metabolic Pathway 
 
 
  
 24 
 
1.6 N-ACETYL-L-CYSTEINE (NAC) 
Apart from acute graft versus host disease and infections, Sinusoidal Obstruction 
Syndrome (SOS), formerly known as Veno Occlusive Disease (VOD) of the liver, is 
one of the more common early complications with a potentially fatal outcome 
following HSCT [42, 90]. SOS is a clinical syndrome consisting of combinations of 
jaundice, ascites, unexplained weight gain, hepatomegaly and upper quadrant 
abdominal pain, as defined by McDonald et al [91] and Jones et al[92]. Low constitute 
levels of glutathione (GSH), the most important intracellular antioxidant, in 
centrilobular hepatocytes together with further GSH exhaustion by the conditioning 
chemotherapy given before HSCT is likely to contribute to the development of 
SOS[93]. In particular, busulphan is known to deplete GSH by 50-60% in murine 
hepatocytes. An increase of cellular levels of GSH has been demonstrated to prevent 
murine busulphan hepatocyte toxicity [94]. This can readily be accomplished by 
administering the GSH precursor N-acetyl-L-cysteine (NAC; Fig. 6)[95]. NAC is 
clinically used as a well-established and nontoxic treatment used to prevent 
hepatotoxicity due to acetaminophen poisoning. It is hence widely available[96] and 
there have been case reports of SOS patients successfully treated with NAC[97]. 
Figure 6: N-acetyl-L-cysteine 
 
Because the desired myeloablative effect of busulphan consists of cytotoxicity towards 
hematopoietic cells, there has been concern that NAC treatment to avoid hepatocyte 
toxicity would impair myeloablation. Busulphan, however, is metabolized in the liver 
through conjugation with GSH catalyzed most effectively by glutation-transferase 
isoenzyme GST-A1 (an isoenzyme not present in hematopoietic cells) [98-99]. 
Accordingly a selective liver protection effect by NAC treatment is probable. In fact, in 
vitro as well as animal in vivo studies have shown that modulation of GSH content in 
hematopoietic cells does not counteract the hematotoxic effect of busulphan[100]. 
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1.7 THERAPEUTIC DRUG MONITORING AND DRUG DOSING 
In many cases a single fixed dose can be prescribed to all adults. Certainly that does not 
imply that every adult needs the same dose for adequate effect or that every adult could 
tolerate the same amount of drug before experiencing toxic effects. Fixed dosing is 
justified if there is a sufficiently wide difference in the amount of drug that produces 
the desirable effect and in that which have toxic effects, i.e. a sufficiently wide 
therapeutic window, to compensate for individual variation in population physiology, 
pharmacokinetics and pharmacodynamics.  
An obvious and relatively simple method of individualizing the dose is to compensate 
for body mass. In a subpopulation with a very wide variation of body mass, such as 
children, this is done for most drugs. In adults, recommendations for a higher or lower 
dose than standard are commonly provided for patients with a body mass that differs 
substantially from the average. 
Several factors complicate the correlation between patient body mass and adequate 
dosage. Most drugs are not evenly distributed in the body. Thus, if a patient has 20 kg 
of extra fat, this may not affect the target organ concentrations of a lipophobic drug.  
Several other factors such as renal, intestinal or hepatic dysfunction and genetic 
differences can affect the needed and tolerated dose more than the patient’s body mass.  
 
 In the late 19th century it was discovered that small animals utilized proportionately 
more oxygen and produced proportionately more heat per kg body mass, than did larger 
animals. Instead, there is a correlation between metabolism and body surface area 
(BSA). Later it was also discovered that BSA was correlated to blood volume and 
circulating plasma proteins. 
BSA was initially recommended in dosage calculations for intravenous fluids, 
electrolytes and blood replacement in children, an approach that was proven to produce 
better outcome than traditional dosing according to body mass alone. In 1958, Donald 
Pinkel proposed that the use of dosing by BSA should replace dosing by weight, which 
had been the traditional method until then [101]. He argued that the determined 
adequate dose of the previously mentioned substances mechlorethamine and 
methotrexate was much better correlated to BSA than to weight in different species 
such as man, rat and mouse. The article had a tremendous impact, and today BSA 
dosing is the most commonly used approach in cancer chemotherapy.  
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It seemed reasonable to adopt BSA dosing for anti-cancer drugs 
at the time. However, the evidence presented does not meet 
modern scientific standards. Inter-species differences in BSA are 
much larger than differences in BSA between human patients, 
and the evaluation of animal toxicity used as a reference did not 
attempt to relate therapeutic doses in various species. There are 
also several methodological problems with estimating BSA. The 
customary practice in the clinic is to use the height-weight 
formula of cousins Du Bois and Du Bois[102]: 
 Area (cm2) = BW (kg)0.425 × height (cm)0.725 × 71.84 
 
The formula was constructed by iteration and graphical interpolation of data from nine 
subjects, who were measured by covering the whole body with soft paper in 1916. 
Even if later studies, comparing the formula to laser scanning measurements of BSA, 
have found a reasonable agreement[103], it still is surprising that hundreds of 
thousands of patients world-wide during almost a hundred years have had their 
cytostatic drug-dose determined by results from a single study on a small number of 
patients using questionable statistic methods. The rationale for BSA dosing strategies 
has not been supported by pharmacokinetic studies and pharmacological 
investigations[104]. It is, however, important to note that for a few cytotoxic drugs such 
as oral busulphan, BSA dosing has not gained widespread use. For oral busulphan, the 
initial dose is calculated according to body mass in most protocols. 
In conclusion, calculations based on BSA or body mass are unlikely to produce 
acceptable estimates of the accurate dose for drugs with a narrow therapeutic window. 
For cytotoxic drugs the therapeutic window is frequently more or less narrow; 
complicating the matter further, the therapeutic and toxic effects are often delayed. 
Although toxicity is commonly regarded as the most important effect to control, the 
risk of under dosing and reduced efficacy must also be considered.  
Obviously more robust dosing strategies have to be developed to improve therapy. 
Such strategies need to be based on predictions of clinical effect.  Pharmacokinetic 
parameters are surrogate markers that are often used since they are clinically 
measurable. Therapeutic drug monitoring means that serum or plasma concentrations 
are measured during therapy and used for correcting consecutive doses. In this manner 
Prof Eugene F duBois 
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it is possible to ensure that the treated patient is subjected to the intended degree of 
drug exposure. Exposure is in this case defined as the area under the plasma 
concentration curve, AUC.  High dose Busulphan regimen is given orally for four days 
with a total dose of 16mg/kg divided into smaller doses. Pharmacokinetic studies of 
oral busulphan have found that bioavailability (AUC oral/AUC iv) varies 2- to 5-fold in 
pediatric patients.[85] Numerous studies have correlated busulphan AUC with regimen 
related toxicity, engraftment and relapse in patients receiving the busulphan and 
cyclophosphamide preparative regimen. A busulphan AUC of 3600-5400ngh/ml in 
partially matched or unrelated bone marrow transplant recipients and 1200-5400ngh/ml 
in allogeneically matched sibling bone marrow transplant patients is desired to 
minimize toxicity and prevent rejection.[46, 105-106] Based on these facts, TDM is 
widely considered standard procedure and a validated method for improving the results 
of HSCT with high dose oral busulphan as part of the conditioning protocol. 
Intravenous formulations of busulphan have recently become available and studies 
have confirmed reduced toxicity problems, apparently due to elimination of the 
unpredictable absorption kinetics of oral busulphan. [107-109]  However, it is likewise 
clear that several sources of interpatient variation in pharmacokinetics remain, such as 
differences in e g metabolism.[105, 110]  
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1.8 LIMITED SAMPLING MODELS (LSM) IN THERAPEUTIC 
DRUG MONITORING   
Traditional TDM is demanding for the lab, the clinical staff and the patient. 
Determination of AUC involves multiple blood samples which must frequently be 
collected from an already anemic patient, sometimes from a pediatric patient. Since 
dose adjustments need to be made as quickly as possible, both the collecting and the 
analyzing of blood samples often have to take place during off-hours when staff is 
reduced. It should be remembered that analysis of pharmacokinetic parameters has in 
general been developed with the preclinical evaluation of new drugs in mind, and not 
for the assessment of doses to individual patients during treatment. None of the above 
complications apply with a healthy study subject in evaluating the pharmacokinetic 
profile of a new drug. On the other hand, as long as the correct decision regarding dose 
adjustment can be reached, precision is not as critical in TDM as when assessing a new 
drug. The needs and complications in TDM are quite different from those in preclinical 
drug evaluation studies and that has prompted new approaches to assessing drug 
exposure in an individual patient as measured by AUC. One important objective is to 
reduce the number of samples and instead use mathematical models for compensating 
the missing data. Several reports on Limited Sampling Models (LSM) have been 
published, but there is a plethora of models and no consensus on which one to use.  
A rough division of models can be made as follows. 
Models based on Bayesian inference: Bayesian statistics are based on the concept of 
aggregating previous knowledge, an informative prior, with current observations for 
making conclusions regarding the likelihood for a certain case. For example, an 
informative prior can be constructed from patient medication, liver enzyme levels and 
what is known in general about busulphan pharmacokinetics. The previously known 
data is allowed to affect the interpretation of the measured plasma concentrations [111-
112]. 
Models based on linear regression: In this case previous results from earlier 
conventional rich sampling TDM is used to construct an equation; the plasma 
concentrations are used as determining factors and AUC as the dependent variable. The 
factors with most impact on the dependent variable are selected for the equation. A 
small initial patient cohort is used and the equation is then verified on a larger cohort 
[113-114]. 
Models based on compartments: These kinds of models are constructed from the 
theoretical principles of pharmacology where the body is visualized as a number of 
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compartments and the drug is absorbed into, transferred between and finally eliminated 
from these compartments at certain rates. Since it is difficult to construct compartment 
models with noisy, sparse sampling data, these models are sometimes combined with a 
Bayesian approach as described earlier.[112]  
Models where a mathematical curve is approximated to the measured dataset: These 
can range from simple trapezoidal rule approximations to elaborate spline constructions 
with correction factors.[115] 
The plasma concentration curve after busulphan treatment is notoriously unpredictable 
and involves not only wide inter- and intraindividual variations in uptake and 
elimination, but also double-peak patterns often seen in drugs with low solubility[116]. 
Reducing the number of samples (and thus the amount of data) on which to base 
estimates of drug exposure will inevitably downgrade precision. Considering the 
benefits of limited sampling, the relevant question is whether this will significantly 
affect the clinical usefulness of TDM. In other words, can the method identify patients 
with busulphan exposure outside the desired interval with enough sensitivity and 
specificity? 
Presently there is no consensus on the optimal method for limited sampling calculations 
or on whether limited sampling is at all acceptable in TDM.   
 30 
 
2. GENERAL AIMS 
The overall aim of this thesis has been to improve high dose chemotherapy; in 
particular, busulphan based conditioning regimens used prior to HSCT. My hope is that 
these findings may benefit patients in need of this treatment and possibly also patients 
treated with chemotherapy for other diseases.    
 
2.1 SPECIFIC AIMS 
• To investigate the myeloablative and immunosuppressive properties of 
treosulfan and to evaluate treosulfan as a candidate drug for use in 
HSCT. 
• To investigate the effect of N-acetyl-L-cysteine in conditioning 
chemotherapy on busulphan kinetics, and hence its effect on 
immunosuppressive or myeloablative properties of the conditioning 
regimen. 
• To evaluate the necessity of TDM and dose adjustment of intravenous 
busulphan, particularly in pediatric patients. 
• To improve limited sampling strategies for TDM of busulphan and to 
evaluate the efficacy of these strategies in estimating drug exposure 
compared to conventional methods.  
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3. MATERIALS AND METHODS 
3.1 ANIMALS  
For the treosulfan study, an animal model was used. Female BALB/c mice, 10 to 12 
weeks old and weighing approximately 20g were purchased from B&K Universal 
Limited (Sweden). The local ethics committee approved the experimental protocol, 
conditions and design. Animals were fed with standard pelleted food and water ad 
libitum.  
 
3.2 PATIENTS  
The patients for the NAC study were all recruited from Huddinge University Hospital 
(presently Karolinska, Huddinge) where they underwent allogeneic SCT between 
October 2000 and May 2002. Six patients were transplanted with stem cells from 
matched unrelated donors, three with stem cells from HLA identical sibling donors and 
one with cord blood. The criterion for inclusion was a high risk for liver toxicity from 
the chemotherapy. Most patients had elevated liver enzymes, but some were included 
due to very high busulphan concentrations in plasma or preexisting hemochromatosis. 
The study on TDM of intravenous busulphan was made in cooperation with the 
Children’s University Hospital in Zurich, Switzerland. Between August 2006 and 
March 2009, thirty-four patients were transplanted in Zurich using a busulphan based 
conditioning regimen in which the busulphan was administered intravenously. The 
majority received allogeneic grafts, but three patients received autologous stem cell 
grafts. According to the underlying disease and current treatment protocols, busulphan 
was used with ATG, fludarabine, cyclophosphamide, melphalan, etoposide or 
combinations thereof. There were 9 patients with malignant disease and 25 patients 
with nonmalignant disease. 
For the limited sampling study, patients were recruited from the center for allogeneic 
stem cell transplantation at Karolinska, Huddinge. All patients had been diagnosed with 
malignant hematological disease and were treated with busulphan as part of the 
conditioning therapy before allogeneic stem cell transplantation. According to local 
guidelines, oral busulphan was administered in two daily doses of 2 mg/kg for four 
days, preceding cyclophosphamide.   
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3.3 ANALYTICAL METHODS  
3.3.1 Cytokines  
We assessed the immunosuppressive effect of treosulfan by examining T-cell 
expression of interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) and interferon-γ 
(IFN-γ) after stimulation with PMA/Ionomycin. We also performed a Mixed 
Lymphocyte Reaction (MLR) study. A clonogeniec assay was used to test the 
myeloablative properties.  
 
3.3.2 Clonogeneic assay  
Both femurs were removed and placed in a sterile Petri dish. Bone marrow was flushed 
from both femurs with Iscove’s modified Dulbecco’s medium. Repeated flushing using 
14-gauge needle formed a single cell suspension. A volume containing 2.5 x 106 cells 
was transferred to sterile tube. Iscove’s modified Dulbecco’s medium was added. The 
mixture was vortexed and transferred to Methocult GF M3534. This media specifically 
encourages the growth of CFU-GM. 0.5 x105 cells were plated in triplicate in 35mm 
Petri dishes and incubated at 37°C, 5% CO2 and 100% humidity. A colony count was 
performed on day seven. 
 
3.3.3 Busulphan determination  
In the Zurich protocol, busulphan plasma concentrations were analyzed using a HPLC-
MS/MS instrument after liquid-liquid extraction into dichloromethane. Separation was 
performed on an Uptisphere 5μ ODB column (125 x 2 mm; Montluçon, France) and 
busulphan was detected as ammonium adducts after electrospray ionization. Spiked 
plasma samples were used to calculate the calibration curve. The calibration curve was 
linear within the range 100-2500 ng/ml. Busulphan concentrations were calculated 
from the calibration curve.   
At Karolinska University Hospital, the Bu concentration was measured using gas 
chromatography. An aliquot of 50µl of internal standard [1,5-
bis(methanesulfonoxy)pentane] at a concentration of 10µg/ml dissolved in acetone was 
added 0.5ml of the plasma. 400µl of n-heptane and 1ml of 8 M sodium iodine were 
added. The reaction between Bu and the internal standard and NaI was carried out at 
70°C for 45 min under magnetic stirring. 200µl of n-heptane was added, and the 
organic phase was removed and analyzed using gas chromatography equipped with 
electron capture detector. The injection temperature was 250oC, the column was 
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operated isothermically at 135oC and there was a detector temperature of 300oC. The 
calibration curve was linear within the range 10-2600ng/ml. 
 
3.3.4 Pharmacokinetics and model development 
Conventional calculation of AUC was made utilizing WinNonLin compartment 
modeling. Models for limited sampling were implemented using Microsoft Visual 
Studio 2010 Professional with the C# programming language and the NMath 
mathematical library from CenterSpace Software Inc. for the Microsoft .NET platform. 
The LSM program was constructed on and compiled for a computer running 32 bit 
Windows 7. 
 
3.4 STATISTICS 
Microsoft Excel was used for simple general statistic calculations of average and 
standard deviations et cetera. For LSM method development and assessment, R version 
2.12.1 from the R Foundation for Statistical Computing and CRAN packages were 
used. In particular R implementations of algorithms for ICC calculus, Bland-Altman 
plots, normality test and a method for finding the most predictive design points in a 
model were utilized.  
 
3.5 EVALUATION OF METHODS 
In clinical medicine there is frequently a need for quantitative measurements upon 
which to base decisions regarding treatment. TDM is a particularly complicated 
example of this, where the results from plasma concentration analyses must be 
processed mathematically to obtain an estimate of drug exposure, which can be used 
for decisions regarding dose adjustments.  Not only must the plasma concentration 
analysis be valid, but also the mathematical method used for calculating AUC. When 
introducing a new method, some lack of agreement with the old methods is inevitable. 
We need to know by how much the new method is likely to differ from the old, so that 
if this difference is not big enough to cause problems in clinical interpretation we can 
replace the old method with the new. How far apart measurements can be without 
leading to problems is a question of clinical judgment. Statistical methods cannot 
answer such a question.  
Historically, accuracy has been used to measure systematic bias while precision has 
been used to measure random error. Agreement measures the “closeness” between 
readings.  The term contains both accuracy and precision.  
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The Correlation Coefficients is one of the most popular indices in statistical literature 
for assessing agreement. Many kinds of correlation coefficients have been proposed. 
There are several correlation coefficients available; the best choice depends on the 
nature of the data to be analyzed. The most commonly used correlation coefficient is 
the concordance correlation coefficient (CCC). The CCC was developed for comparing 
two series of observations, generating continuous data on each subject[117]. The CCC 
is suitable when the subjects and the observers are randomly chosen but not when the 
observers are replaced by fixed AUC calculation algorithms (methods). A more 
appropriate parametric method for this situation is the Intraclass Correlation Coefficient 
which can be used for calculating agreement as well as consistency (precision)[118]. 
The ICC is based on analysis of variance (ANOVA) calculations, and different models 
are used depending on the data. The following model applies for assessing agreement 
for fixed observations on random targets. This type of the ICC is based on a two-way 
mixed model ANOVA[119].  An ANOVA separates the variance of the observations 
into components derived from interpatient variance and intrapatient variance. The 
intrapatient variance, in two-way analysis, can be further divided into variance from 
interaction between patient and method and residual variance. The equation for the 
agreement parameter 𝜌 is seen in (5). The parameter can be estimated from an analysis 
of variance table and the sum of squares as described in (6). 
 
𝜌 = 𝜎𝑃2
𝜎𝑃
2+𝜎𝑀
2 +𝜎𝐼
2+𝜎𝐸
2    (5) 
𝜌=correlation 
𝜎𝑃
2=variance of patients 
𝜎𝑀
2= variance of methods 
𝜎𝐼
2= variance of patient-method interaction 
𝜎𝐸
2= variance of the residual error 
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𝐼𝐶𝐶 = 𝐵𝑀𝑆−𝐸𝑀𝑆
𝐵𝑀𝑆+(𝑘−1)𝐸𝑀𝑆+𝑘
𝑛
(𝑀𝑀𝑆−𝐸𝑀𝑆)  (6) 
ICC=Intraclass Correlation Coefficient 
BMS=Between Patients Mean Square 
EMS=Residual Error Mean Square 
MMS=Methods Mean Square 
k= number of methods compared (in this case 2 each comparison) 
n=number of patients (23) 
 
Bland-Altman plots give graphical representations of precision and accuracy in relation 
to exposure range[120]. A Bland-Altman plot is a plot showing the difference of the 
two methods against the mean result. The plots provide important information on how 
well the limited sampling models perform in specific areas of interest. Patients with 
busulphan exposure in the vicinity of the cut-off point for dose adjustments can be 
identified, and the agreement of the LSM to the reference for these patients can be 
studied. The main disadvantage with a Bland-Altman plot is the difficulty in making a 
quantitative objective comparison between the different LSM performances. The 
choice of scale is also vital for an informative plot.  
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4. RESULTS  
Treosulfan and busulphan induce a high and persistent degree of myeloablation in 
comparison with cyclophosphamide. Treosulfan was more effective in depletion of 
splenic B and T cells as compared to busulphan and cyclophosphamide, and T cells 
isolated from the spleens of treosulfan- or busulphan-treated mice were not responsive 
to allogeneic cells.  
 
 
 
Treosulfan induces durable myeloablation in mice (Fig 7). Mice were treated with 
treosulfan (solid diamond and dashed lines), busulphan (solid squares with dotted 
lines), and cyclophosphamide (solid triangle symbols and solid lines). Control animals 
were left untreated (empty squares).  
 
Figure 7: CFU-GM colony-forming unit granulocyte macrophages 
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Figure 8: Splenic B- and T-cell depletion respectively 
 
Treosulfan induces splenic B- and T-cell depletion in mice (Fig 8). Mice were treated 
with treosulfan (solid diamond and dashed lines), busulphan (solid squares with dotted 
lines), and cyclophosphamide (solid triangle symbols and solid lines). Control animals 
were left untreated (solid square symbols on the Y axes). 
 
After the administration of NAC during conditioning to patients with increased risk 
for hepatotoxicity and SOS due to pre-transplant liver disorders or elevated liver 
enzymes, no side effects related to the NAC infusions were observed and busulphan 
concentrations were not affected. All patients became pancytopenic and engrafted 
with 100% donor cells (Fig 9). 
 
 
Figure 9: Course of transplantation for NAC treated patients 
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In patients treated with intravenous busulphan, the busulphan dose had to be adjusted 
at least once for 23/34 patients (68%) studied. The need for dose adjustment could not 
be predicted by age or weight as shown in figure 10.  
Figure 10: AUC compared to age and weight (respectively) 
 
 
A comparison of three different principles for constructing a limited sampling model 
with the industry standard/rich sampling/WinNonLin compartment model as 
reference proved that there is a substantial variation in quality and reliability of AUC 
estimate depending on the choice of algorithm and model. Bland Altman plots for 
each model (Fig 11-12) showed that using limited sampling with a one compartment 
model or a modified Purves curve fitting model, one can arguably obtain a clinically 
useful estimate. Using an average of both methods tends to improve agreement to the 
reference method further. Comparing the average to the reference method (Fig 13) we 
found an intraclass correlation coefficient (ICC) of 0.86. In contrast, the ICC for the 
regression model was 0.62. Bland-Altman plots found that using this method would 
frequently lead to other decisions regarding dose reduction than if the decisions were 
based on the reference rich sampling model. Further analysis of data found that only 
one of the 23 examined cases had an AUC estimate from the combined AUC that 
differed from the reference method in a manner that would affect decisions regarding 
dosing of busulphan.   
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Figure 11: Agreement of estimates from combining the compartment and the curve 
fitting model 
 
 
 
Figure 12: Agreement of the three sample linear regression model 
 
 
 
Limited sampling 
model 
Estimated ICC 95% CI lower limit for 
ICC 
95% CI upper limit for 
ICC 
Non-Compartment 
curve-fitting model 
0.82 0.61 0.92 
One-Compartment 
model 
0.77 0.53 0.90 
Linear Regression 
model 
0.62 0.16 0.84 
Using Average AUC 
from Compartment + 
Non-Compartment 
curve fitting model 
0.86 0.69 0.94 
 
Figure 13: Intraclass correlation coefficient for the various kinds of lsm with rich 
sampling as reference 
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5. DISCUSSION 
The thesis deals with different ways to reduce toxicity and adverse effects associated 
with chemotherapy as conditioning before HSCT, particularly in busulphan 
chemotherapy. The least radical measure would be to improve dosing strategy and 
assure that every patient is given the optimal dose. Due to the unpredictable 
bioavailability and metabolism of busulphan this is, however, a formidable task. I have 
found that only part of the interpatient variations in exposure can be overcome with 
intravenous administration. It can be speculated that this may be the result of 
unpredictable phase II metabolism and glutathione conjugation capacity. An 
unexpected high risk for SOS also raises concern about adverse effects of additives 
needed for intravenous formulations of busulphan. Regardless of the possible future 
replacement of oral busulphan with intravenous formulations, the development of 
improved strategies for therapeutic drug monitoring is important. Since the number of 
samples is one of the most important factors in determining resource demand as well as 
patient discomfort, it is highly desirable to limit the number of blood samples collected 
during therapeutic drug monitoring. The catch is that reducing the number of samples 
increases the size of plasma concentration curve segments necessary to simulate in 
between measured concentrations and causes a single measurement error to have more 
impact on the final parameter estimate. The question is: How few samples are enough 
for a reasonably safe and accurate pharmacokinetic evaluation? The answer to the 
question must be somewhat subjective and perhaps should be different for different 
patient populations. Therapeutic drug monitoring guided by rich sampling, i.e. 8-12 
samples, has been demonstrated to benefit clinical outcome. Ideally, any change in this 
procedure should be verified by studies to provide the same benefits. In reality, testing 
any possible procedure in this manner would raise several difficult ethical questions. 
Instead, it makes sense to search for a method that shows as much agreement as 
possible with the verified procedure in use, and especially to assess how frequently 
decisions based on the new model could differ from decisions based on the verified 
model. I investigated limited sampling model calculations based on three different 
principles and their respective agreement with rich sampling for actual patients. The 
best possible algorithm should be used in future research and direct studies on the 
clinical benefits of TDM based on limited sampling models. I found that there is reason 
to believe that only very few patients would not get the same dose adjustments with 
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estimates from the proposed LSM strategy as they would with estimates from rich 
sampling.  
Adding drugs to reduce toxicity from chemotherapy is also a possibility, but this may 
impair the desired therapeutic effect. In HSCT that may be just as fatal as any toxicity. 
Detoxification of busulphan is almost entirely dependent on glutathione conjugation in 
the liver. As stated earlier, the unpredictable metabolism of the drug is probably caused 
primarily by this fact as well as by variations in nutritional status and hepatic function 
between patients. Glutathione hepatocellular content can be replenished by 
administration of NAC, and this is done routinely in some intoxications, most notably 
paracetamol intoxication. The time from intoxication to NAC treatment is vital. 
According to current treatment guidelines for paracetamol intoxication, treatment 
should not be delayed until signs of hepatic damage occur, since this renders NAC 
treatment virtually ineffective. In a pilot study of ten patients we showed that NAC 
concomitant with conditioning chemotherapy did not reduce the myeloablative 
properties of treatment warranting further studies with concomitant NAC to high risk 
patients before signs of liver damage. It is my firm belief that this possibility has to date 
not been sufficiently explored. 
The most radical approach to handling busulphan toxicity would be to simply replace 
the drug with another drug capable of myeloablation but without the variations in 
bioavailability and metabolism, and with less hepatotoxicity. Ideally this drug would 
also be soluble and easy to administer intravenously. In fact, there is such a candidate 
drug available: treosulfan. An animal model allows a much more invasive and complete 
assessment of myeloablative and immunosuppressive properties in vivo than would be 
ethically possible in human subjects. The study on treosulfan was an important step 
towards in-clinic studies of actual patients. It confirmed the expectations of treosulfan 
properties on hematopoietic cells and immune system, indicating that it is suitable as a 
drug for use in HSCT conditioning regimens. The drug has lately gained widespread 
use in the clinic in various regimens for HSCT conditioning for patients with a high 
risk of hepatotoxicity.     
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6. CONCLUSIONS 
• Treosulfan possesses both myeloablative and immunosuppressive properties, 
and our findings affirmed treosulfan as a candidate drug for conditioning prior 
to bone marrow transplantation. Lately treosulfan has come in clinical use for 
patients at high risk (especially for liver toxicity), and it is increasingly 
accepted as an interesting new alternative to busulphan. 
• NAC therapy is safe and does not impair the myeloablative effect of 
busulphan during conditioning prior to SCT. None of the patients in the study 
developed VOD or liver failure. Increased liver enzymes during conditioning 
decreased or normalized in all patients. In spite of these interesting findings, 
the number of patients was too small to provide evidence of the beneficial 
effects of NAC during conditioning.  
• TDM is also essential when busulphan is administered intravenously. It is 
clear that TDM increases the efficacy and safety of intravenous busulphan-
based conditioning protocols in pediatric HSCT recipients. The unexpectedly 
high risk for SOS warrants further studies to determine whether additives in 
intravenous formulations could be the cause. 
• Decisions regarding dose adjustments based on the proposed approach of 
using an average of a compartment model and a curve fitting model will 
seldom differ from decisions based on rich sampling. The conclusion is that 
the clinical use of this implementation of a limited sampling algorithm with 
four samples for busulphan therapeutic drug monitoring is justifiable, 
considering the practical aspects of using rich sampling. In contrast, it was 
found that using the regression model based on three samples would quite 
frequently impact decisions regarding (particularly) dose reductions. This 
means that the clinical usefulness of TDM based on the latter model cannot be 
verified.  
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7. FUTURE PERSPECTIVES 
Developing models for therapeutic drug monitoring in order to individualize dose and 
treatment will certainly benefit patients treated with cytostatic drugs that have a narrow 
therapeutic window.  
Even if monoclonal antibodies, tyrosine kinases and other designed drugs will be 
increasingly important for the treatment of malignant disease in the future, it is likely 
than cytostatic agents will remain necessary for most patients. In addition, cytostatic 
drugs are not the only drugs to have a narrow therapeutic window.  
Individually optimized therapy is an important concept that must be used much more 
than it is today, and it there is a potential for extending this concept to new areas as 
well. I believe that an important step in facilitating this is to make TDM more expedient 
and less costly. Developing limited sampling models for use in TDM is the most 
obvious way to achieve this. 
Validating the benefits of TDM in new areas of cytostatic treatment requires clinical 
studies and accepted standardized techniques that can realistically be used in daily 
clinical practice. One future perspective is to use a LSM in this kind of study, providing 
direct evidence of the benefits from LSM TDM for certain patients and treatments. 
 
7.1 ON THE USE OF COMPUTERS IN MEDICAL RESEARCH 
The calculations necessary for the evaluation of plasma concentrations cannot 
practically be done without the use of computers. With an approachable modern high 
level language such as C# there is, however, a new possibility for researchers to 
construct Windows based applications and to achieve individually tailored solutions.  
I have chosen to supply the final version of the Windows application used for AUC 
calculus freely for download in the hope that this will facilitate the use and 
implementation of my findings. In this I was inspired by the practice in the scientific 
field of statistics, where scientists have long provided implementations of their work as 
R scripts. R is an open-source statistical programming language. 
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